—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Please provide your email address to receive an email when new articles are posted on . NCCN recommends osimertinib plus chemotherapy or lazertinib plus amivantamab-vmjw as first-line options for EGFR ...

Dr. Sandip Patel discusses findings from a real-world study of biomarker testing in early-stage resected non-small cell lung cancer in the U.S. Although biomarker testing in early-stage non-small cell ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...

In this presentation the speaker will discuss latest developments in NSCLC precision therapy and biomarker landscape, and importance of NGS in NSCLC biomarker testing. He will review the NSCLC ...

Please provide your email address to receive an email when new articles are posted on . Gaps in access remain, though, as almost half of patients did not receive next-generation sequencing. “These ...

PD-L1 TPS ≥50% enriches for anti–PD-(L)1 monotherapy benefit, but threshold-based use risks misclassification due to dynamic expression and inter-assay/inter ...